Grey Wolf Therapeutics completes £2.5 million financing to accelerate development of therapies targeting ERAP2
Grey Wolf Therapeutics, a drug discovery biotechnology company focused on developing first-in-class therapies for immuno- oncology (IO), has completed a £2.5 million ($3.3 million) Series A2 financing round with existing healthcare investors Andera Partners and Canaan. The new funding will allow the company to accelerate development of therapies targeting endoplasmic reticulum aminopeptidase 2 (ERAP2), following […]
